Literature DB >> 1375972

Ondansetron in carcinoid syndrome.

A J Platt, R M Heddle, M O Rake, H Smedley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1375972     DOI： 10.1016/0140-6736(92)91235-z

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial.

Authors:  G Stacher; U Weber; G Stacher-Janotta; P Bauer; K Huber; A Holzäpfel; G Krause; C Steinborn
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

2.  Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.

Authors:  Barbara Kiesewetter; Heying Duan; Wolfgang Lamm; Alexander Haug; Philipp Riss; Andreas Selberherr; Christian Scheuba; Markus Raderer
Journal:  Oncologist       Date:  2018-08-31

3.  Mechanical stimulation activates Galphaq signaling pathways and 5-hydroxytryptamine release from human carcinoid BON cells.

Authors:  M Kim; N H Javed; J G Yu; F Christofi; H J Cooke
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 4.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.

Authors:  S B Saslow; J S Scolapio; M Camilleri; L A Forstrom; G M Thomforde; D D Burton; J Rubin; H C Pitot; A R Zinsmeister
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

6.  QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells.

Authors:  Hitoshi Doihara; Katsura Nozawa; Ryosuke Kojima; Eri Kawabata-Shoda; Toshihide Yokoyama; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-06-09       Impact factor: 3.396

Review 7.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.